Goldman Sachs Collaborates with Anthropic on AI Cybersecurity Risks After Model Delay
Goldman Sachs is working with Anthropic to evaluate cybersecurity threats from the company's new AI model, Mythos, which was not released publicly due to concerns. The model prompted a meeting between US banking leaders and top officials last week. The bank views AI as a long-term opportunity despite the risks.
Substrate placeholder — needs reviewGoldman Sachs is collaborating with Anthropic to assess cybersecurity risks associated with the AI company's latest model, Mythos. The model, described as highly advanced, was not released publicly last week due to potential vulnerabilities. Instead, Anthropic is providing limited previews to select organizations.
The decision followed concerns that the system's capabilities could allow non-experts to exploit weaknesses in major operating systems. Goldman Sachs, which has access to an early preview, is coordinating with Anthropic and its security vendors to address these threats. Cybersecurity remains a core focus for the bank, with ongoing investments in resilience.
Last week, leaders from major US banks met with Federal Reserve Chair Jerome Powell and Treasury Secretary Scott Bessent to discuss the risks posed by the model. The meeting addressed broader cybersecurity issues in the financial sector. Such discussions between banks and government officials on these topics have occurred for years.
During the bank's first-quarter earnings call, Goldman Sachs stated that it is supplementing its cyber infrastructure with support from the US government and AI model developers. The bank is accelerating investments in these areas. Despite the concerns, the institution expressed optimism about AI's potential to improve processes and efficiency in the medium to long term.
The rollout of advanced AI models like Mythos highlights ongoing challenges in balancing innovation with security in the financial industry. Banks are increasingly integrating AI technologies, which requires enhanced protections against potential exploits. This collaboration aims to mitigate risks while exploring AI's benefits for business operations.
Anthropic's approach of limiting access to the model provides time for thorough testing and safeguards. Financial institutions, including Goldman Sachs, are among the organizations receiving previews to evaluate real-world applications. The incident underscores the need for coordinated efforts between technology developers and regulated sectors.
Transparency
Rewrite shows mild valence skew in emphasizing AI risks and vulnerabilities, with neutral facts presented through a cautious lens on innovation.
Valence skew: systematically highlights potential threats to AI model
Anthropic's cautious withholding of Mythos demonstrates responsible AI development, enabling banks like Goldman to proactively enhance cybersecurity and harness efficiency gains.
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Sources framed at 32 → our rewrite 28. We stripped 4 points of framing the sources carried in.
Story details
Related Stories
U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
news.sky.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
observer.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…